 Zee News |
Rahul’s speech impressive, he spoke from heart, India Inc says
Times of India NEW DELHI: India Inc was impressed by Congress leader Rahul Gandhi’s maiden interaction with corporate leaders on Thursday saying he came across as a sincere leader and this can form the basis for future engagement with the industry. “It was a very … Rahul’s speech impressive, he spoke from heart: India IncZee News Rahuls Speech Impressive, He Spoke From Heart, India Inc SaysSiliconindia.com Gandhi says growth in ‘beehive’ India must help poorDAWN.com NDTV all 174 news articles » |
Rate of Nephrectomy at Lymph Node Dissection Is Declining – Renal and Urology News
Rate of Nephrectomy at Lymph Node Dissection Is DecliningRenal and Urology NewsOver the last 30 years, the incidence of nephrectomy at post-chemotherapy (PC) retroperitoneal lymph node dissection (RPLND) has steadily declined, according to research pub…
Anti-HIV Antibodies May Spur AIDS Vaccine Development – TIME
 TIME |
Anti-HIV Antibodies May Spur AIDS Vaccine Development
TIME From the moment of infection, the immune system goes on alert and immediately generates antibodies designed to attach to and destroy HIV. And for the first few weeks, these antibodies are successful, eliminating all but a few viruses that remain hidden … Antibodies ‘map’ to vaccine for AIDS foundThe Japan Times Breakthrough Reported in Creating Antibodies to Fight HIV/AIDSLatinos Post Findings on ‘Broadly Neutralizing Antibodies‘ May Be Key to HIV VaccineAIDSmeds.com HIV/AIDS Treatment News Bloomberg –Nature.com –Counsel & Heal all 38 news articles » |
Former England 'keeper sidelined with blood clot – Times of India
|
Former England ‘keeper sidelined with blood clot
Times of India LONDON: Former England goalkeeper Paul Robinson is set to be out for the rest of the season and well into the next after developing a blood clot on the lung, his club, English Championship side Blackburn Rovers, said. “Paul is set for a lengthy spell … |
Your Students, Your Schools — West Des Moines and Waukee – DesMoinesRegister.com
Your Students, Your Schools — West Des Moines and WaukeeDesMoinesRegister.comThey include the United States, Guatemala, Mexico, El Salvador, Ecuador, Argentina, Ghana, Bosnia, Germany, Italy, Egypt, Jordan, Iraq, Kenya, Russia, Sudan, Uganda, India, P…
Male baldness indicates heart disease risk – Times of India
Times of IndiaMale baldness indicates heart disease riskTimes of IndiaThe researchers trawled the Medline and the Cochrane Library databases for research published on male pattern baldness and coronary heart disease, and came up with 850 possible studi…
Multiple Sklerose: Daclizumab HYP halbiert die Wahrscheinlichkeit von Schüben – Informationsdienst Wissenschaft (Pressemitteilung)
|
Multiple Sklerose: Daclizumab HYP halbiert die Wahrscheinlichkeit von Schüben
Informationsdienst Wissenschaft (Pressemitteilung) Patienten mit einer schubförmig remittierenden Multiplen Sklerose profitieren von einer Behandlung mit dem monoklonalen Antikörper Daclizumab HYP (high-yield process). Dies ergab die heute im The Lancet online veröffentlichte SELECT-Studie. Erfolg versprechend: Neues Medikament gegen Multiple Skleroseinnovations report |
16/6-idiotype expressing antibodies induce brain inflammation and cognitive … – 7thSpace Interactive (press release)
16/6-idiotype expressing antibodies induce brain inflammation and cognitive …7thSpace Interactive (press release)The 16/6-idiotype (16/6-Id) of the human anti-DNA antibody was found to induce experimental lupus in naive mice, manifested by production…
B-cell targeted therapeutics in clinical development – 7thSpace Interactive (press release)
B-cell targeted therapeutics in clinical development7thSpace Interactive (press release)B-cell depletion with the CD20 antibody rituximab has provided clinical proof of concept that targeting B cells and the humoral response can result in significant b…
Biologic therapy for autoimmune diseases: an update – 7thSpace Interactive (press release)
Biologic therapy for autoimmune diseases: an update7thSpace Interactive (press release)This review provides an update of the recent literature on the new biologic therapies available. The review concentrates on nine drugs: tocilizumab, rituximab, ofatu…